



**AMICUS THERAPEUTICS, INC.**  
**6 Cedar Brook Drive**  
**Cranbury, New Jersey 08512**

May 25, 2007

**Via EDGAR and Facsimile**

United States Securities and Exchange Commission  
Division of Corporate Finance  
100 F Street, NE  
Washington, D.C. 20549  
Attention: Suzanne Hayes

**Re: Amicus Therapeutics, Inc,**  
**Registration Statement on Form S-1, as amended**  
**File No. 333-141700**

**Registration Statement on Form 8-A**  
**File No. 001-33497**

Ladies and Gentlemen:

Pursuant to Rule 461 of the Securities Act of 1933, as amended, and Rule 12(b)-6 of the Securities Exchange Act of 1934, as amended, Amicus Therapeutics, Inc., a Delaware corporation (the "Company"), hereby requests that the effectiveness of the Company's above-referenced Registration Statement on Form S-1, as amended, and Registration Statement on Form 8-A be accelerated to **3:00 p.m. Eastern Daylight Time, on Wednesday, May 30, 2007**, or as soon as practicable thereafter, unless you are orally or in writing notified to the contrary by the Company prior to such date and time.

Morgan Stanley & Co. Incorporated and Merrill Lynch & Co. are the principal underwriters in connection with the Company's above-referenced Registration Statement on Form S-1. We enclose with this request a letter from the underwriters joining in the Company's request for acceleration of the Registration Statement.

The Company hereby acknowledges that:

- should the Securities and Exchange Commission (the "Commission") or the staff of the Commission (the "Staff"), acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
  - the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
-

- the Company may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Should you have any questions regarding this request, please do not hesitate to contact Julio E. Vega (617-951-8901) or Meerie M. Joung (617-951-8840) of Bingham McCutchen LLP.

Sincerely,

**AMICUS THERAPEUTICS, INC.**

/s/ Douglas A. Branch

---

Douglas A. Branch, Esq.

Vice President & General Counsel

cc: Julio E. Vega, Esq., *Bingham McCutchen LLP*  
Meerie M. Joung, Esq., *Bingham McCutchen LLP*  
Patrick O'Brien, Esq., *Ropes & Gray LLP*

---

MORGAN STANLEY & CO. INCORPORATED  
1585 BROADWAY  
NEW YORK, NY 10036

MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED  
4 WORLD FINANCIAL CENTER  
NEW YORK, NY 10080

May 25, 2007

**VIA EDGAR AND FACSIMILE**

United States Securities and Exchange Commission  
Division of Corporate Finance  
100 F Street, NE  
Washington, D.C. 20549  
Attention: Suzanne Hayes

**Re: Amicus Therapeutics, Inc,  
Registration Statement on Form S-1, as amended  
File No. 333-141700**

**Registration Statement on Form 8-A  
File No. 001-33497**

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the "Act"), on behalf of Morgan Stanley & Co. Incorporated, Merrill Lynch, Pierce, Fenner & Smith Incorporated, J.P. Morgan Securities Inc., Lazard Capital Markets LLC and Pacific Growth Equities, LLC, we hereby join Amicus Therapeutics, Inc. (the "Company") in requesting that the effectiveness of the Company's above-referenced Registration Statement on Form S-1, as amended, and Registration Statement on Form 8-A be accelerated to **3:00 p.m. Eastern Daylight Time, on Wednesday, May 30, 2007**, or as soon as practicable thereafter, unless you are orally or in writing notified to the contrary by the Company prior to such date and time.

Pursuant to Rule 460 under the Act, please be advised that between May 17, 2007 and May 25, 2007, the undersigned effected the following approximate distribution of copies of the Preliminary Prospectus dated May 17, 2007:

19,344 copies to prospective underwriters, institutional investors, dealers and others.

This is to further advise you that the underwriters have complied and will continue to comply with SEC release No. 33-4968 and Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

The Commission is further advised that the amount of compensation to be allowed or paid to the underwriters, to be disclosed in the Prospectus filed pursuant to Rule 424(b) under the Act, will not exceed an amount that has been cleared with the National Association of Securities Dealers, Inc.

Very truly yours,

Morgan Stanley & Co. Incorporated  
Merrill Lynch, Pierce, Fenner & Smith  
Incorporated

Acting severally on behalf of themselves  
and the several Underwriters

By: Morgan Stanley & Co. Incorporated

By: /s/ John D. Tyree

Name: John D. Tyree  
Title: Executive Director

By: Merrill Lynch, Pierce, Fenner &  
Smith Incorporated

By: /s/ Adam Chazan

Name: /s/ Adam Chazan  
Title: Vice President